Zoetis Inc.
ZTSAPI behind this page
ZTS Q2 2025 request
Playground key active
/api/financials?ticker=ZTS&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 2,460 | 2,361 | +4.2% |
Show Product Lines breakouts |
|||
| Animal health diagnostics | 110 | 103 | +6.8% |
| Anti-infectives | 219 | 264 | -17.0% |
| Cattle | 320 | 350 | -8.6% |
| Companion Animal [Member] | 1,788 | 1,649 | +8.4% |
| Companion Animal [Member] · International | 612 | 569 | +7.6% |
| Companion Animal [Member] · U.S. | 1,176 | 1,080 | +8.9% |
| Contract manufacturing & human health | 34 | 18 | +88.9% |
| Dermatology | 463 | 418 | +10.8% |
| Dogs and Cats | 1,716 | 1,581 | +8.5% |
| Fish | 74 | 62 | +19.4% |
| Horses | 72 | 68 | +5.9% |
| Livestock [Member] | 638 | 694 | -8.1% |
| Livestock [Member] · International | 458 | 466 | -1.7% |
| Livestock [Member] · U.S. | 180 | 228 | -21.1% |
| Manufactured Product Other | 22 | 20 | +10.0% |
| Medicated Feed Additives | 5 | 74 | -93.2% |
| Other Non Pharmaceuticals [Member] | 63 | 65 | -3.1% |
| Other pharmaceutical | 172 | 153 | +12.4% |
| Pain and sedation | 217 | 221 | -1.8% |
| Parasiticides | 673 | 600 | +12.2% |
| Poultry | 103 | 132 | -22.0% |
| Swine [Member] | 119 | 130 | -8.5% |
| Total products and services | 2,426 | 2,343 | +3.5% |
| Vaccines | 504 | 445 | +13.3% |
Show Business Segments breakouts |
|||
| International · Operating Segments | 241 | 237 | +1.7% |
| International · Operating Segments | 1,070 | 1,035 | +3.4% |
| U.S. · Operating Segments | 1,356 | 1,308 | +3.7% |
Show Geography breakouts |
|||
| AU | 83 | 83 | 0.0% |
| BR | 93 | 99 | -6.1% |
| CA | 73 | 75 | -2.7% |
| CL | 36 | 31 | +16.1% |
| CN | 72 | 68 | +5.9% |
| DE | 58 | 58 | 0.0% |
| ES | 37 | 33 | +12.1% |
| FR | 33 | 34 | -2.9% |
| GB | 77 | 73 | +5.5% |
| IT | 38 | 36 | +5.6% |
| JP | 45 | 39 | +15.4% |
| MX | 38 | 46 | -17.4% |
| Other developed markets | 162 | 138 | +17.4% |
| Other emerging markets | 225 | 222 | +1.4% |
| Total geographical area | 2,426 | 2,343 | +3.5% |
| US | 1,356 | 1,308 | +3.7% |
| Cost of Revenue | 649 | 668 | -2.8% |
Show Business Segments breakouts |
|||
| International · Operating Segments | 314 | 342 | -8.2% |
| U.S. · Operating Segments | 208 | 232 | -10.3% |
| Selling, General & Administrative | 617 | 581 | +6.2% |
| Research And Development Expense Excluding Acquired In Process Cost | 172 | 171 | +0.6% |
| Amortization Of Intangible Assets Not Associated With Single Function | 33 | 35 | -5.7% |
| Restructuring Charges And Acquisition And Divestiture Related Costs | 30 | 42 | -28.6% |
| Interest Expense | 53 | 59 | -10.2% |
| Non-Operating Income (Expense) | 4 | 25 | -84.0% |
| Income Before Taxes | 902 | 780 | +15.6% |
Show Business Segments breakouts |
|||
| All Other Segments | -134 | -142 | +5.6% |
| International · Operating Segments | 583 | 518 | +12.5% |
| U.S. · Operating Segments | 930 | 872 | +6.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -321 | -299 | -7.4% |
| Operating Segments | 1,513 | 1,390 | +8.8% |
| Income Tax Expense (Benefit) | 184 | 156 | +17.9% |
| Net Income | 718 | 624 | +15.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 718 | 624 | +15.1% |
| Net Income | 718 | 624 | +15.1% |
| EPS (Basic) | 1.61 | 1.37 | +17.5% |
| EPS (Diluted) | 1.61 | 1.37 | +17.5% |
| Wtd Avg Shares (Basic) | 445.1 | 455.5 | -2.3% |
| Wtd Avg Shares (Diluted) | 445.5 | 456 | -2.3% |
| Common Stock Dividends Per Share Declared | 0.5 | 0.43 | +15.7% |
| Gross Profit (Q) | — | — | — |
Show Business Segments breakouts |
|||
| International · Operating Segments | 756 | 693 | +9.1% |
| U.S. · Operating Segments | 1,148 | 1,076 | +6.7% |
| Operating Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| International · Operating Segments | 173 | 175 | -1.1% |
| U.S. · Operating Segments | 218 | 204 | +6.9% |
| Other Non-Operating Income (Expense) | 1 | -2 | +150.0% |
| Comprehensive Income | 858 | 620 | +38.4% |
| Foreign Currency Transaction Gain Loss Before Tax | 14 | 18 | -22.2% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,435 | 1,574 | -8.8% |
| Accounts Receivable | 1,540 | 1,383 | +11.4% |
| Inventory | 2,439 | 2,452 | -0.5% |
| Other Assets Current | 509 | 467 | +9.0% |
| Total Current Assets | 5,923 | 6,202 | -4.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,537 | 3,200 | +10.5% |
| Operating Lease Right-of-Use Assets | 302 | 222 | +36.0% |
| Goodwill | 2,758 | 2,739 | +0.7% |
Show Geography breakouts |
|||
| International [Member] | 1,243 | 1,224 | +1.6% |
| US | 1,515 | 1,515 | 0.0% |
| Deferred Tax Assets | 617 | 366 | +68.6% |
| Other Non-Current Assets | 267 | 210 | +27.1% |
| Total Assets | 14,479 | 14,165 | +2.2% |
| Intangible Assets | 858 | 1,011 | -15.1% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 656 | 801 | -18.1% |
| Other Intangible Assets | 86 | 82 | +4.9% |
| Trademarks And Trade Names | 116 | 128 | -9.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 1,075 | 1,226 | -12.3% |
| Current Liabilities | |||
| Current Portion of Long-Term Debt | 1,350 | — | — |
| Accounts Payable | 508 | 420 | +21.0% |
| Dividends Payable Current | 222 | 197 | +12.7% |
| Other Accrued Liabilities Current | 770 | 704 | +9.4% |
| Employee Related Liabilities Current | 293 | 276 | +6.2% |
| Taxes Payable Current | 93 | 82 | +13.4% |
| Other Liabilities Current | 130 | 93 | +39.8% |
| Total Current Liabilities | 3,366 | 1,797 | +87.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 5,231 | 6,563 | -20.3% |
| Deferred Tax Liabilities | 156 | 175 | -10.9% |
| Operating Lease Liabilities | 210 | 181 | +16.0% |
| Accrued Income Taxes Noncurrent | 265 | 267 | -0.7% |
| Other Non-Current Liabilities | 274 | 222 | +23.4% |
| Total Liabilities | 9,502 | 9,205 | +3.2% |
| Stockholders' Equity | |||
| Common Stock | 5 | 5 | 0.0% |
| Treasury Stock Value | -8,226 | -6,464 | -27.3% |
| Additional Paid-In Capital | 1,203 | 1,146 | +5.0% |
| Retained Earnings | 12,872 | 11,124 | +15.7% |
| Accumulated Other Comprehensive Income | -877 | -845 | -3.8% |
| Total Stockholders' Equity | 4,977 | 4,966 | +0.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 4,977 | 4,960 | +0.3% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 72 | 84 | -14.3% |
| Accumulated Net Unrealized Investment Gain Loss | -45 | 36 | -225.0% |
| Accumulated Other Comprehensive Income | -877 | -845 | -3.8% |
| Accumulated Translation Adjustment | -904 | -967 | +6.5% |
| Additional Paid In Capital | 1,203 | 1,146 | +5.0% |
| Common Stock | 5 | 5 | 0.0% |
| Retained Earnings | 12,872 | 11,124 | +15.7% |
| Treasury Stock Common | -8,226 | -6,464 | -27.3% |
| Total Liabilities & Equity | 14,479 | 14,165 | +2.2% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 242 | 253 | -4.3% |
Show Business Segments breakouts |
|||
| All Other Segments | 24 | 20 | +20.0% |
| International · Operating Segments | 48 | 48 | 0.0% |
| U.S. · Operating Segments | 45 | 45 | 0.0% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 58 | 65 | -10.8% |
| Operating Segments | 93 | 93 | 0.0% |
| Stock-Based Compensation | 39 | 37 | +5.4% |
| Asset Impairment Charges | 33 | 13 | +153.8% |
Show Restructuring Cost And Reserve breakouts |
|||
| Facility Closing | 22 | — | — |
| Disposal Group Not Discontinued Operation Gain Loss On Disposal | 3 | 22 | -86.4% |
Show Disposal Group Classification breakouts |
|||
| Disposal Group Disposed Of By Sale Not Discontinued Operations · Medicated Feed Additives | 3 | — | — |
| Inventory Write Down | 32 | 42 | -23.8% |
| Deferred Income Taxes | 12 | -144 | +108.3% |
| Other Non-Cash Items | -5 | 11 | -145.5% |
| Change in Accounts Receivable | -194 | -112 | -73.2% |
| Change in Inventory | -168 | -115 | -46.1% |
| Increase Decrease In Other Operating Assets | -162 | -35 | -362.9% |
| Change in Accounts Payable | 24 | 20 | +20.0% |
| Increase Decrease In Other Operating Liabilities | -104 | -88 | -18.2% |
| Increase Decrease In Accrued Taxes Payable | -28 | -30 | +6.7% |
| Net Cash from Operations | 1,073 | 1,097 | -2.2% |
| Investing Activities | |||
| Capital Expenditures | -327 | -272 | -20.2% |
| Payments To Acquire Business Two Net Of Cash Acquired | -10 | -8 | -25.0% |
| Payments To Acquire Investments | -3 | -3 | 0.0% |
| Payments For Proceeds From Hedge Investing Activities | -76 | 21 | -461.9% |
| Proceeds From Divestiture Of Businesses Net Of Cash Divested | -4 | — | — |
| Other Investing Activities | -2 | -2 | 0.0% |
| Net Cash from Investing | -422 | -263 | -60.5% |
| Excise Tax Accrued On Net Share Repurchased Not Paid | 7 | 8 | -12.5% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 58 | 26 | +123.1% |
| Right Of Use Asset Obtained In Exchange For Finance Lease Liability | 1 | — | — |
| Dividends Payable Current And Noncurrent | 222 | 197 | +12.7% |
| Financing Activities | |||
| Share Based Compensation Related Proceeds Net Of Taxes Paid On Withholding Shares | -12 | -12 | 0.0% |
| Share Repurchases | -781 | -872 | +10.4% |
| Payments Of Ordinary Dividends | -447 | -395 | -13.2% |
| Proceeds From Payments For Other Financing Activities | -1 | — | — |
| Net Cash from Financing | -1,241 | -1,287 | +3.6% |
| Supplemental | |||
| Income Taxes Paid | 475 | 481 | -1.2% |
| Interest Paid | 137 | 138 | -0.7% |
| Operating Lease Payments | 34 | 30 | +13.3% |
| Finance Lease Principal Payments | 2 | 1 | +100.0% |
| Unpaid Capital Expenditures | 3 | 3 | 0.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 38 | -14 | +371.4% |
| Net Change in Cash | -552 | -467 | -18.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,435 | 1,574 | -8.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.